As Novo Nordisk A/S expands its presence in Massachusetts, the Danish pharmaceutical giant is also growing its partnerships ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

In a late-stage clinical trial, a drug similar to Ozempic was shown to reduce body mass index in kids ages 6 to 11 with ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

Biopharmaceutical company Korro Bio, Inc. (KRRO) announced Monday a collaboration with Danish healthcare company Novo Nordisk A/S ...

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...

Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.